EuroBiotech Report: The Trump effect, Cancer buyout talk, Merck KGaA reject advances and TiGenix cell therapy data


Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with President Trump. Staff at medical journal The BMJ became the latest to express concern about Trump’s effect on global drug regulation and research when they published an editorial about his administration. Nordic Nanovector CEO Luigi Costa talked up the level of third-party interest in experimental non-Hodgkin lymphoma candidate Betalutin. Apitope posted phase 2a data on the multiple sclerosis drug Merck KGaA walked away from last year, teeing it up to move into phase 2b. TiGenix and Takeda presented 52-week data on their stem cell therapy. And more. Nick Taylor

1. BMJ warns of global impact of Trump on R&D, regulation

Editors at The BMJ have warned President Trump’s policies could damage biomedical research and regulation around the world. The journal has committed to fostering open debate and supporting those who “speak truth to power” to counter the actions of an administration it sees as heading for a “head-on collision with the scientific and health communities.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

2. Cancer player Nordic Nanovector stokes takeover talk

Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma (NHL) candidate Betalutin. Costa claimed the level of interest in the asset is growing as clinical data accumulates, triggering a double-digit jump in Nanovector’s stock price.

3. After Merck KGaA rejection, Apitope advances MS drug

Apitope has posted phase 2a data on the multiple sclerosis drug Merck KGaA walked away from last year. The single-arm study linked immunotolerizing peptide-based candidate ATX-MS-1467 to a drop in total and new neurological lesions, giving Apitope the confidence to forge ahead with plans to run a phase 2b trial.

4. Takeda, TiGenix stem cell therapy shows sustained effect

Takeda and TiGenix have presented 52-week data on their allogeneic expanded adipose-derived stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas. The data show the Cx601 stem cells continue to outperform placebo one year after administration.

And more articles of note>>

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.